Summary:
A double-blind, placebo-controlled, Phase IIb, multi-center, 10-week prospective study to evaluate the efficacy and safety of NOE-105 in adult male patients with childhood onset fluency disorder.
Criteria:- Be 18-50 years old
- Be male
- Have childhood onset fluency disorder (stuttering)
- Discontinue all medications used to treat stuttering for at least 14 dyas prior to screening
- Have a history of stuttering for 2 years with onset conistent to developmental in nature before age 8 years
Qualified Participants May Receive:
- Up to $2,810 for time and travel
- No insurance needed and transportation available